Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

1.

Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer.

Saramäki O, Willi N, Bratt O, Gasser TC, Koivisto P, Nupponen NN, Bubendorf L, Visakorpi T.

Am J Pathol. 2001 Dec;159(6):2089-94.

PMID:
11733359
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Mapping the amplification of EIF3S3 in breast and prostate cancer.

Nupponen NN, Isola J, Visakorpi T.

Genes Chromosomes Cancer. 2000 Jun;28(2):203-10.

PMID:
10825005
[PubMed - indexed for MEDLINE]
3.

Expression and copy number analysis of TRPS1, EIF3S3 and MYC genes in breast and prostate cancer.

Savinainen KJ, Linja MJ, Saramäki OR, Tammela TL, Chang GT, Brinkmann AO, Visakorpi T.

Br J Cancer. 2004 Mar 8;90(5):1041-6.

PMID:
14997205
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Fluorescence in situ hybridization analysis of c-myc amplification in stage TNM prostate cancer in Japanese patients.

Sato H, Minei S, Hachiya T, Yoshida T, Takimoto Y.

Int J Urol. 2006 Jun;13(6):761-6.

PMID:
16834657
[PubMed - indexed for MEDLINE]
5.

Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer.

Nupponen NN, Porkka K, Kakkola L, Tanner M, Persson K, Borg A, Isola J, Visakorpi T.

Am J Pathol. 1999 Jun;154(6):1777-83.

PMID:
10362802
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients.

Ribeiro FR, Henrique R, Martins AT, Jerónimo C, Teixeira MR.

Eur Urol. 2007 Jul;52(1):116-25. Epub 2006 Oct 10.

PMID:
17070983
[PubMed - indexed for MEDLINE]
7.

The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer.

Saramäki OR, Tammela TL, Martikainen PM, Vessella RL, Visakorpi T.

Genes Chromosomes Cancer. 2006 Jul;45(7):639-45.

PMID:
16575874
[PubMed - indexed for MEDLINE]
8.

Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.

Qian J, Hirasawa K, Bostwick DG, Bergstralh EJ, Slezak JM, Anderl KL, Borell TJ, Lieber MM, Jenkins RB.

Mod Pathol. 2002 Jan;15(1):35-44.

PMID:
11796839
[PubMed - indexed for MEDLINE]
Free Article
9.

PTK2 and EIF3S3 genes may be amplification targets at 8q23-q24 and are associated with large hepatocellular carcinomas.

Okamoto H, Yasui K, Zhao C, Arii S, Inazawa J.

Hepatology. 2003 Nov;38(5):1242-9.

PMID:
14578863
[PubMed - indexed for MEDLINE]
10.

Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer.

Reiter RE, Sato I, Thomas G, Qian J, Gu Z, Watabe T, Loda M, Jenkins RB.

Genes Chromosomes Cancer. 2000 Jan;27(1):95-103.

PMID:
10564591
[PubMed - indexed for MEDLINE]
11.
12.

Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer.

Tsuchiya N, Slezak JM, Lieber MM, Bergstralh EJ, Jenkins RB.

Genes Chromosomes Cancer. 2002 Aug;34(4):363-71.

PMID:
12112525
[PubMed - indexed for MEDLINE]
13.

Identification of genetic markers for prostatic cancer progression.

Alers JC, Rochat J, Krijtenburg PJ, Hop WC, Kranse R, Rosenberg C, Tanke HJ, Schröder FH, van Dekken H.

Lab Invest. 2000 Jun;80(6):931-42.

PMID:
10879743
[PubMed - indexed for MEDLINE]
14.

Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization.

Jenkins RB, Qian J, Lieber MM, Bostwick DG.

Cancer Res. 1997 Feb 1;57(3):524-31.

PMID:
9012485
[PubMed - indexed for MEDLINE]
Free Article
15.

[Relationship between chromosome 8 alterations and Gleason score in prostatic adenocarcinoma].

Zeng X, Wu SF, Xu Q, Xiao Y, Liu TH.

Zhonghua Bing Li Xue Za Zhi. 2006 Sep;35(9):523-8. Chinese.

PMID:
17134545
[PubMed - indexed for MEDLINE]
16.

DNA sequence amplification in human prostate cancer identified by chromosome microdissection: potential prognostic implications.

Van Den Berg C, Guan XY, Von Hoff D, Jenkins R, Bittner, Griffin C, Kallioniemi O, Visakorpi, McGill, Herath J, et al.

Clin Cancer Res. 1995 Jan;1(1):11-8.

PMID:
9815882
[PubMed - indexed for MEDLINE]
Free Article
17.

Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone.

Alers JC, Krijtenburg PJ, Rosenberg C, Hop WC, Verkerk AM, Schröder FH, van der Kwast TH, Bosman FT, van Dekken H.

Lab Invest. 1997 Nov;77(5):437-48.

PMID:
9389787
[PubMed - indexed for MEDLINE]
18.

HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization.

Ross JS, Sheehan C, Hayner-Buchan AM, Ambros RA, Kallakury BV, Kaufman R, Fisher HA, Muraca PJ.

Hum Pathol. 1997 Jul;28(7):827-33.

PMID:
9224752
[PubMed - indexed for MEDLINE]
19.

Fluorescence in situ hybridization evaluation of c-myc and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients.

Miyoshi Y, Uemura H, Fujinami K, Mikata K, Harada M, Kitamura H, Koizumi Y, Kubota Y.

Prostate. 2000 May 15;43(3):225-32.

PMID:
10797498
[PubMed - indexed for MEDLINE]
20.

Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer.

El Gammal AT, Brüchmann M, Zustin J, Isbarn H, Hellwinkel OJ, Köllermann J, Sauter G, Simon R, Wilczak W, Schwarz J, Bokemeyer C, Brümmendorf TH, Izbicki JR, Yekebas E, Fisch M, Huland H, Graefen M, Schlomm T.

Clin Cancer Res. 2010 Jan 1;16(1):56-64. doi: 10.1158/1078-0432.CCR-09-1423. Epub 2009 Dec 22.

PMID:
20028754
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk